中国医院用药评价与分析2023，Vol.23Issue(12)：1499-1503,5.DOI:10.14009/j.issn.1672-2124.2023.12.018
依达拉奉右莰醇治疗急性缺血性脑卒中的药物经济学评价
Pharmacoeconomic Evaluation of Edaravone Dexborneol in the Treatment of Acute Ischemic Stroke
张美燕 1张红楠 1武小琦 1付淑莲 1张卓 1张磊1
作者信息
- 1. 河北医科大学第一医院药剂科,石家庄 050000
- 折叠
摘要
Abstract
OBJECTIVE:To evaluate the efficacy and economic value of edaravone dexcamphorol in the treatment of acute ischemic stroke based on real-world data,so as to provide scientific basis for rational drug use in clinical treatment of stroke and government decision-making in China.METHODS:Clinical data of 354 patients with acute ischemic stroke admitted into the hospital from Nov.15th,2021 to Aug.14th,2022 were retrospectively analyzed and divided into the control group(with basic treatment)and observation group(combined with edaravone dexcamphorol on the basis of control group)according to treatment regimen.The National Institutes of Health Stroke Scale score(NIHSS),Modified Rankin Scale score(mRS),swallowing function score,cost-effectiveness ratio,qubornality-adjusted life years(QALY)of two groups were compared.The influence of each parameter variable on stability of the research results was observed by single factor sensitivity analysis and probability sensitivity analysis.RESULTS:After treatment,the mRS score and swallowing function score of the observation group were lower than those of the control group,and the decrease of NIHSS score was greater than that of control group,with statistically significant differences(P<0.05).Compared with the control group,the incremental cost-effectiveness ratio of treatment regimen in the observation group was 44 649.51 yuan/QALY,lower than the willingness to pay threshold(242 928 yuan)set in the study.Results of single factor sensitivity analysis and probability sensitivity analysis were consistent with the results of basic analysis.CONCLUSIONS:For patients with acute ischemic stroke,the combination of edaravone dexcamphorol in the context of basic therapy can effectively improve the overall benefit of treatment and has more pharmacoeconomic advantages.关键词
药物经济学评价/急性缺血性脑卒中/依达拉奉右莰醇/敏感性分析Key words
Pharmacoeconomic evaluation/Acute ischemic stroke/Edaravone dexcamphorol/Sensitivity analysis分类
医药卫生引用本文复制引用
张美燕,张红楠,武小琦,付淑莲,张卓,张磊..依达拉奉右莰醇治疗急性缺血性脑卒中的药物经济学评价[J].中国医院用药评价与分析,2023,23(12):1499-1503,5.
